HC Wainwright started coverage on shares of DENTSPLY SIRONA Inc. (NASDAQ:XRAY) in a research note released on Tuesday morning, MarketBeat Ratings reports. The brokerage issued a buy rating and a $74.00 price objective on the medical instruments supplier’s stock.

Other equities research analysts also recently issued research reports about the stock. Cleveland Research raised shares of DENTSPLY SIRONA from a neutral rating to a buy rating in a research note on Tuesday, May 23rd. BidaskClub raised shares of DENTSPLY SIRONA from a hold rating to a buy rating in a research note on Friday, June 30th. Zacks Investment Research raised shares of DENTSPLY SIRONA from a sell rating to a hold rating in a research note on Thursday, March 30th. Finally, Goldman Sachs Group, Inc. (The) downgraded shares of DENTSPLY SIRONA from a neutral rating to a sell rating and reduced their target price for the company from $60.00 to $55.00 in a research note on Tuesday, May 23rd. One research analyst has rated the stock with a sell rating, three have issued a hold rating and ten have assigned a buy rating to the company. DENTSPLY SIRONA has an average rating of Buy and a consensus target price of $67.92.

Shares of DENTSPLY SIRONA (XRAY) opened at 65.11 on Tuesday. The firm has a 50-day moving average of $63.25 and a 200-day moving average of $61.43. DENTSPLY SIRONA has a one year low of $55.00 and a one year high of $65.68. The company has a market cap of $14.93 billion, a price-to-earnings ratio of 41.90 and a beta of 1.27.

DENTSPLY SIRONA (NASDAQ:XRAY) last announced its earnings results on Tuesday, May 9th. The medical instruments supplier reported $0.49 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.50 by $0.01. DENTSPLY SIRONA had a net margin of 9.42% and a return on equity of 7.37%. The firm had revenue of $900.50 million during the quarter, compared to analysts’ expectations of $916.55 million. During the same period in the prior year, the company posted $0.69 EPS. The company’s revenue was up 16.6% compared to the same quarter last year. Equities research analysts forecast that DENTSPLY SIRONA will post $2.84 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This news story was originally published by Watch List News and is the property of of Watch List News. If you are reading this news story on another domain, it was stolen and republished in violation of US & international trademark and copyright laws. The correct version of this news story can be accessed at https://www.watchlistnews.com/dentsply-sirona-inc-xray-now-covered-by-hc-wainwright/1444165.html.

The business also recently declared a quarterly dividend, which will be paid on Friday, October 13th. Stockholders of record on Friday, September 29th will be issued a $0.0875 dividend. This represents a $0.35 dividend on an annualized basis and a dividend yield of 0.54%. The ex-dividend date of this dividend is Thursday, September 28th. DENTSPLY SIRONA’s payout ratio is presently 22.58%.

In other news, CEO James G. Mosch sold 50,600 shares of the company’s stock in a transaction dated Monday, April 24th. The shares were sold at an average price of $63.49, for a total value of $3,212,594.00. Following the transaction, the chief executive officer now directly owns 105,083 shares in the company, valued at $6,671,719.67. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Corporate insiders own 1.99% of the company’s stock.

Several hedge funds and other institutional investors have recently bought and sold shares of XRAY. Howard Hughes Medical Institute boosted its position in DENTSPLY SIRONA by 134.9% in the first quarter. Howard Hughes Medical Institute now owns 2,751 shares of the medical instruments supplier’s stock worth $172,000 after buying an additional 1,580 shares during the last quarter. Penserra Capital Management LLC boosted its position in DENTSPLY SIRONA by 9.5% in the first quarter. Penserra Capital Management LLC now owns 2,760 shares of the medical instruments supplier’s stock worth $172,000 after buying an additional 240 shares during the last quarter. Howland Capital Management LLC bought a new position in DENTSPLY SIRONA during the first quarter worth approximately $203,000. TNB Financial bought a new position in DENTSPLY SIRONA during the first quarter worth approximately $259,000. Finally, Atria Investments LLC boosted its position in DENTSPLY SIRONA by 6.3% in the first quarter. Atria Investments LLC now owns 4,473 shares of the medical instruments supplier’s stock worth $279,000 after buying an additional 265 shares during the last quarter. Hedge funds and other institutional investors own 94.89% of the company’s stock.

DENTSPLY SIRONA Company Profile

DENTSPLY SIRONA Inc is a manufacturer of professional dental products and technologies. The Company develops, manufactures, and markets solutions offering, including dental and oral health products, as well as other consumable medical devices. It operates through two segments: Dental and Healthcare Consumables, and Technologies.

Analyst Recommendations for DENTSPLY SIRONA (NASDAQ:XRAY)

Receive News & Ratings for DENTSPLY SIRONA Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DENTSPLY SIRONA Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.